相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Activable Targeted Protein Degradation Platform Based on Light-triggered Singlet Oxygen
Silong Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
HER3-addicted tumors: how biotechs are closing in
Elie Dolgin
NATURE BIOTECHNOLOGY (2022)
PDTAC: Targeted Photodegradation of GPX4 Triggers Ferroptosis and Potent Antitumor Immunity
Sijin Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Thirty Years of HER3: From Basic Biology to Therapeutic Interventions
Heidi M. Haikala et al.
CLINICAL CANCER RESEARCH (2021)
Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface
Devan Diwanji et al.
NATURE (2021)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2020)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
Samuel W. Brady et al.
CANCER BIOLOGY & THERAPY (2015)
Nanoparticles in Photodynamic Therapy
Sasidharan Swarnalatha Lucky et al.
CHEMICAL REVIEWS (2015)
Triplet photosensitizers: from molecular design to applications
Jianzhang Zhao et al.
CHEMICAL SOCIETY REVIEWS (2013)
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition
B. N. Rexer et al.
ONCOGENE (2011)
Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
Joan T. Garrett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Unraveling the Biologic and Clinical Complexities of HER2
John W. Park et al.
CLINICAL BREAST CANCER (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles
Priti S. Hegde et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Natalia V. Sergina et al.
NATURE (2007)
Photodynamic therapy and anti-tumour immunity
Ana P. Castano et al.
NATURE REVIEWS CANCER (2006)
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
Wenle Xia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
GE Konecny et al.
CANCER RESEARCH (2006)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
